Achieve Life Sciences is developing and commercializing smoking cessation aids. More than 87% of lung cancer deaths, 61% of pulmonary deaths and 32% of coronary heart disease deaths are attributable to smoking and exposure to secondhand smoke. Even e-cigarettes are harmful due to chemical exposure that causes lung injury. Achieve is dedicated to addressing this global smoking health and nicotine addiction epidemic through the commercialization of their product cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic receptors in the brain to reduce withdrawal symptoms. A Phase 3 clinical trial using cytisinicline is now in progress for smoking cessation. 

<p>Achieve Life Sciences is developing and commercializing smoking cessation aids. More than 87% of lung cancer deaths, 61% of pulmonary deaths and 32% of coronary heart disease deaths are attributable to smoking and exposure to secondhand smoke. Even e-cigarettes are harmful due to chemical exposure that causes lung injury. Achieve is dedicated to addressing this global smoking health and nicotine addiction epidemic through the commercialization of their product cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic receptors in the brain to reduce withdrawal symptoms. A Phase 3 clinical trial using cytisinicline is now in progress for smoking cessation. </p>


Achieve Life Sciences

Founded: 2015
Location: Bothell, WA
Employee range: 1-50
Clinical stage: Clin3
Therapy area: Smoking cessation
Drug types: ABU
Lead product: Cytisinicline
Funding: 10-100M

Drug notes:

About:

Jobs: